These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 31107982

  • 1. Efficacy and safety of anagrelide as a first-line drug in cytoreductive treatment-naïve essential thrombocythemia patients in a real-world setting.
    Ito T, Hashimoto Y, Tanaka Y, Nakaya A, Fujita S, Satake A, Nakanishi T, Konishi A, Hotta M, Yoshimura H, Ishii K, Hashimoto A, Kondo T, Omura H, Shinzato I, Tanaka T, Nomura S.
    Eur J Haematol; 2019 Aug; 103(2):116-123. PubMed ID: 31107982
    [Abstract] [Full Text] [Related]

  • 2. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL, Marton É, Plander M, Szendrei T.
    Orv Hetil; 2016 Feb 28; 157(9):336-41. PubMed ID: 26895801
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
    Ge X, Yang L, Jin J, Qian W, Li J, Yang R, Cao X, Jiang B, Wang Z, Hou M, Zhang W, Xiao Z, Zhao Y, Gao D, Zhang X, Wang S, Sun A, Fu J, Su L, Li K.
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jul 28; 36(7):547-52. PubMed ID: 26304075
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anagrelide and Mutational Status in Essential Thrombocythemia.
    Iurlo A, Cattaneo D, Orofino N, Bucelli C, Fabris S, Cortelezzi A.
    BioDrugs; 2016 Jun 28; 30(3):219-23. PubMed ID: 27041108
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
    Mazzucconi MG, Baldacci E, Latagliata R, Breccia M, Paoloni F, Di Veroli A, Cedrone M, Anaclerico B, Villivà N, Porrini R, Montefusco E, Andriani A, Montanaro M, Scaramucci L, Spadea A, Rago A, Cimino G, Spirito F, Santoro C.
    Eur J Haematol; 2020 Sep 28; 105(3):335-343. PubMed ID: 32441419
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
    Kwiatkowski J, Kuliszkiewicz-Janus M, Rymer W, Jaźwiec B, Małecki R.
    Pharmacology; 2021 Sep 28; 106(5-6):316-322. PubMed ID: 33691325
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
    Gotic M, Egyed M, Gercheva L, Warzocha K, Kvasnicka HM, Achenbach H, Wu J.
    Cardiovasc Toxicol; 2021 Mar 28; 21(3):236-247. PubMed ID: 33123978
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience].
    Kornblihtt LI, Vassallu PS, Heller P, Molinas FC.
    Medicina (B Aires); 2002 Mar 28; 62(3):231-6. PubMed ID: 12150005
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
    Hernández-Boluda JC, Pereira A, Cervantes F, Gómez M, Arellano-Rodrigo E, Alvarez-Larrán A, Ferrer-Marín F, Kerguelen A, Márquez JA, Antelo ML, Besses C, Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN).
    Ann Hematol; 2013 Jun 28; 92(6):771-5. PubMed ID: 23354997
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.